Therapeutic vaccination against chronic viral infections

Lancet Infectious Diseases

Volumn 2, Issue 6, 2002, Pages 353-367

  Vandepapelière, Pierre ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DNA VACCINE; INACTIVATED VACCINE; PEPTIDE VACCINE; UNCLASSIFIED DRUG; VACCINE; VIRUS VECTOR; VIRUS VECTOR VACCINE;

ACTIVE IMMUNIZATION; ANTIGEN ANTIBODY COMPLEX; CELL DESTRUCTION; CELLULAR IMMUNITY; CYTOPATHOGENIC EFFECT; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; HEPATITIS B VIRUS; HERPES SIMPLEX VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOSTIMULATION; IMMUNOTHERAPY; PATHOGENESIS; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS INFECTION; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 0036274692     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(02)00289-X     Document Type: Review

References (169)

1. Chronic hepatitis B
2. Epidemiology of genital human papillomavirus infection
3. The role of papillomaviruses in human anogenital cancer
4. Herpes simplex virus type 2 in the U.S. 1976-1994
5. Immune response to the hepatitis B virus: Infection, animal models, vaccination
6. Viral clearance without destruction of infected cells during acute HBV infection
7. Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection
8. Hepatitis B virus immunopathogenesis
9. Influence of T-helper cell subsets and crossregulation in hepatitis B virus infection
10. HLA antigens and cervical carcinoma
11. Immunology of papillomavirus infection
12. Neutralizing activity of antibodies against the major herpes simplex virus type 1 glycoproteins
13. Interferon-a production appears to predict time of recurrence of herpes labialis
14. T cell responses to herpes simplex viruses in humans
15. Augmentation of immunity to herpes simplex virus by in vivo administration of interleukin 2
16. Rapid Turnover of plasma virions and CD4 lymphocytes in HIV-1 Infection
17. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
18. HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies
19. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection
20. Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- and anti-hepatitis B surface antibody-positive
21. Therapeutic vaccination for treatment of chronic hepatitis B: Rationale, review and prospects for future development
22. Immunological events in regressing genital warts
23. Human papillomavirus in the immunosuppressed
24. Infiltration of cervical cancer tissue with human papillomavirus-specific cytotoxic T-lymphocytes
25. The efficacy and safety of Skinner herpes simplex virus vaccines towards modulation of herpes genitalis; report of a prospective double-blind placebo-controlled trial
26. Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: Factors influencing efficacy
27. A genetically activated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary, and recurrent HSV-2 disease
28. Effect of S28463 as an adjuvant for an immunotherapeutic HSV glycoprotein D (gD) DNA vaccine: Reduction of recurrent genital HSV disease in guinea pigs
29. High levels of anti-HIV-1 memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1 infected long-term nonprogressors
30. Developments in preclinical AIDS vaccine efficacy models
31. Cellular immune responses to HIV-1
32. Immune responses in HIV-exposed seronegatives: Have they repelled the virus?
33. Quantitation of HIV-1-specific cytotoxic lymphocytes and plasma load of viral RNA
34. Antiviral pressure exerted by HIV-1 specific cytotoxic lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus
35. Vaccine therapy: Result of a questionnaire to American physicians
36. Prospects for the control of AIDS by immunizing seropositive individuals
37. Herpes simplex virus vaccines
38. Therapeutic vaccines for control of human papillomavirus chronic infections
39. The basis for HIV immunotherapeutic vaccines
40. Vaccine therapy in recurrent herpes simplex
41. Immunotherapy with inactivated polyvalent herpes vaccines
42. Placebo-controlled study with subunit herpes simplex virus vaccine in subjects suffering from frequent herpetic recurrences
43. A placebo-controlled trial of vaccination with a mixed glycoprotein herpes simplex virus type 1 vaccine for the modulation of recurrent genital herpes
44. Clinical efficacy of a herpes simplex subunit vaccine
45. A randomized double-blind, placebo-controlled phase I trial of a herpes simplex virus purified glycoprotein (gDI) vaccine
46. Development of a herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use
47. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes
48. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: Results of a placebo-controlled vaccine trial
49. Herpes simplex virus glycoprotein treatment of recurrent genital herpes
50. Persistence of humoral and cellular immune response and booster effect following vaccination with herpes simplex (gD2t) candidate vaccine with MPL
51. Immunogenicity and reactogenicity of recombinant herpes simplex virus type-2 (HSV-2) glycoprotein D vaccine with monophosphoryl lipid A in HSV-seronegative and seropositive subjects
52. Prophylactic vaccination against genital herpes disease with adjuvanted recombinant glycoprotein D vaccine: Two randomized controlled trials
53. Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent and latent genital infections with herpes simplex virus type 2 in guinea pigs
54. Immunomodulatory effects of HSV2 glycoprotein D in HSV1 infected mice: Implications for immunotherapy of recurrent HSV infection
55. Immunotherapy of acute and recurrent herpes simplex virus type 2 infection with an adjuvant-free form of recombinant glycoprotein D-interleukin-2 fusion protein
56. Immunization with replication-defective mutants of herpes simplex virus type 1: Sites of immune intervention in pathogenesis of challenge virus infection
57. Immunization against genital herpes disease with a replication-defective mutant of HSV-2
58. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus)
59. Replication, establishment of latency and induced reactivation of herpes simplex virus gl 34.5 deletion mutants in rodent models
60. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1
61. Evaluation of a live attenuated recombinant virus RAV9395 as a herpes simplex virus type 2 vaccine in guinea pigs
62. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: Long-term protection and effect of revaccination
63. Protection of guinea pigs from primary and recurrent herpes simplex virus (HSV) type 2 cutaneous disease with vaccinia virus recombinants expressing HSV glycoprotein D
64. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B
65. Antibody response and protective capacity of plasmid vaccines expressing three different herpes simplex virus glycoproteins
66. Hepatitis B vaccine administered to chronic carriers of hepatitis B surface antigen
67. A controlled study of anti-HBV vaccine therapy in chronic hepatitis B infection
68. Immunotherapy of chronic hepatitis B by anti HBV vaccine
69. Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles
70. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant
71. Phase 1 study of a potent adjuvanted hepatitis B vaccine (HBV/MF59) for therapy of chronic hepatitis B
72. Efficacy of a third generation preS1/preS2 containing HBV carrier (Hepagene) as immunotherapy for HBeAg positive chronic hepatitis
73. Immunotherapy of chronic hepatitis B in Asian patients using a novel triple antigen hepatitis B vaccine (Hepacare)
74. Vaccine therapy for chronic hepatitis B: Immunogenicity and safety of two candidate vaccines in human healthy volunteers
75. Characterization of HBV envelope specific humoral and cellular immune responses induced by vaccination of healthy adult volunteers
76. Effector function, kinetics and epitope hierarchy of HBV envelope specific, CD9 + T cells induced by vaccination of healthy, adult volunteers
77. CY-1899: A therapeutic vaccine for chronic hepatitis B
78. Phase 1 safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device
79. Hepatitis B vaccine and antiH-Bs complex as approach for vaccine therapy
80. Cross-clade immune responses after immunization with a whole-killed gp 120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects
81. HIV-1-specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated gp-120-depleted HIV-1 in incomplete Freund's adjuvant
82. A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected Thai subjects with CD4-cell counts of > 300
83. T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune)
84. The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomised, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs
85. Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorophioate-guanine dinucleotide immunostimulatory sequences of DNA
86. AIDS vaccine moves into phase 3 trials
87. Heterologous prevention of disease in rhesus monkeys using a multicomponent subunit AIDS vaccine
88. A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV-seropositive subjects
89. Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic patients
90. Clade B-based HIV-vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers
91. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN tm/gag/protease LAI (ALVAC-HIV,vCP2050 followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection
92. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in healthy volunteers
93. Discontinuation of HAART after a course of therapeutic vaccination with ALVAC 1452 and rgp160 may be associated with delayed viral rebound kinetics
94. Safety and immunogenicity study on vCP1542/gp160 vaccine in patients treated with HAART for over 2 years
95. CD8+ lymphocyte antiviral activity in monkeys immunized with SIV recombinant poxvirus vaccines: Potential role in vaccine efficacy
96. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques
97. A therapeutic HIV vaccine using coxsackie-HIV recombinants: A possible new strategy
98. Recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques
99. Induction of HIV-1-specific T-helper responses and type 1 cytokine secretion following therapeutic vaccination of macaques with a recombinant fowlpoxvirus co-expressing interferon-gamma
100. Reduction of simian-human immunodeficieny virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus ankara vaccination
101. A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques
102. Cellular cytotoxic response induced by DNA vaccination in HIV-infected patients
103. Immune responses in asymptomatic HIV-1 infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment
104. Enhancement of cellular immune response in HIV-1 seropositive individuals. A DNA-based trial
105. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys
106. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
107. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
108. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques
109. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins or immunotherapy for cervical cancer
110. Boosting with recombinant vaccinia increases HPV- 16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines
111. Early evaluation of two schedules of administration of a novel therapeutic vaccine for chronic hepatitis B
112. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts
113. Evaluation of the safety and immunogenicity of a recombinant HPV-II L1 virus like particle vaccine in healthy adult volunteers
114. Cell-mediated immune responses to recombinant HPV-16 E6E7hh protein generated by immunization with chelating Iscomatrix' adjuvant
115. Immunotherapy of human papillomavirus type 16 associated carcinoma using adjuvant-free fusion protein encoding M. Bovis BCG HSP65 and HPV16 E7
116. Immune response to human papillomavirus type 16 early protein E2 following immunization with adjuvant MF 59 in a mouse model
117. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7
118. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-induced cells
119. A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1 -and Th2-type responses in immunized mice in the absence of oil based adjuvants
120. Development of DNA vaccines against HPV-16 L1
121. Intracutaneous genetic vaccination with a combination of cottontail rabbit papillomavirus E1, E2, E6 and E7 genes induces protective anti-papillornavirus immunity in rabbits
122. CXCR4 and CCR5 expression on CD4+ T-cells in vivo and HIV-1 antigen beta-chemokine production in vitro after treatment with HIV-1 immunogen (REMUNE)
123. Enhanced immunogenicity of a recombinant genital warts vaccine adjuvanted with monophosphoryl lipid A
124. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
125. Therapeutic potential of protein and adjuvant vaccinations on tumour growth
126. Papillomavirus virus-like particles as anticancer vaccines
127. Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles; induction of cytoxic T cells and specific tumor protection
128. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine
129. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine
130. Interferon-a production appears to predict time of recurrence of herpes labialis
131. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection
132. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
133. A phase 1 evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with human immunodeficiency virus infection
134. A phase 1 trial of HPV 6 B virus like particles as immunotherapy for genital warts
135. Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults
136. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against plasmodium falciparum malaria
137. Protective vaccination against primary, and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1
138. Solid matrix-antibody-antigen complex can clear viraemia and antigenaemia in persistent duck hepatitis B virus infection
139. The position of heterologous epitopes inserted in Hepatitis B core particles determines their immunogenicity
140. Production of chimeric human papillomavirus 16 E4 - Hepatitis B core recombinant particles
141. The hepatitis virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection
142. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection: Induction of a primary cytotoxic T lymphocyte response in humans
143. Cervical cancer vaccines: Emerging concepts and developments
144. Vaccination with IIPV16 peptides of patients with advanced cervical carcinoma: Clinical evaluation of a phase I-II trial
145. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic 'l' lymphocyte responses, after peptide vaccination of patients with cervical carcinoma
146. A phase II IIPV16 E6 and E7 peptides vaccination in patients with advanced cervical cancer
147. A phase I trial of a HPV peptide vaccine for women with high grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive
148. Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production
149. DNA vaccines
150. DNA-mediated immunization: Prospects for hepatitis B vaccination
151. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes
152. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene
153. Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease
154. DNA immunization against experimental genital herpes simplex virus infection
155. Simian immunodeficiency virus DNA vaccine trial in macaques
156. DNA vaccination as anti-HIV immunotherapy in infected chimpanzees
157. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes
158. Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen
159. Progress in the development of an HIV vaccine
160. Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): Dependence on route of challenge exposure
161. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B
162. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection
163. Induction of antibody to the MHV surface antigen in chronic WHV carriers by vaccination with alum-adjuvanted WHsAg alone and in combination with the antiviral drug, 1-(2-fluoro-5-methyl-b-L-arabinofuransoyl) uracil (L-FMAU)
164. Structured treatment interruptions in antiretroviral management of HIV-1
165. Immune control of HIV-1 after early treatment of acute infection
166. Study protocol for the evaluation of the potential for durable viral suppression after quadruple HAART with or without HIV vaccination: The QUEST study
167. Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein vaccine